Should infliximab be used as an adjuvant to IVIG in the treatment of children with kawasaki disease who are at high risk for resistance to conventional therapy?

Shelby Davies, Gabrielle Gold-Von Simson

Research output: Contribution to journal › Letter › peer-review

8 Scopus citations

Fingerprint

Dive into the research topics of 'Should infliximab be used as an adjuvant to IVIG in the treatment of children with kawasaki disease who are at high risk for resistance to conventional therapy?'. Together they form a unique fingerprint.